Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01977625 · ClinicalTrials.gov registry record · Phase 4
LDX and Functional Magnetic Resonance Imaging (fMRI in Menopausal Women
A Phase 4 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 4
- Development phase
- 18
- Enrollment target
NCT01977625: Completed Phase 4 study, sponsored by University of Pennsylvania.
NCT01977625 is a Phase 4 study that has completed, run by University of Pennsylvania. The registered enrollment target is 18 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01977625, a Phase 4 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 18 participants
- Enrollment target
Study Summary
This study seeks to assess the effects of lisdexamfetamine (trademark name: Vyvanse; LDX) on executive function and prefrontal cortex activation in menopausal women ages 45-57, who report subjective cognitive difficulties. This protocol will recruit women from Dr. Epperson's ongoing study, Protocol #812470, to examine the impact of LDX on brain activation during performance of cognitive tasks specifically probing prefrontal cortex function.
Interventions
- OTHER Placebo
- DRUG Lisdexamfetamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2011-12 |
| Est. Completion | 2014-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01977625
The ClinicalTrials.gov registry entry for NCT01977625 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01977625 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01977625 about?
NCT01977625 is a clinical study titled "LDX and Functional Magnetic Resonance Imaging (fMRI in Menopausal Women". This study seeks to assess the effects of lisdexamfetamine (trademark name: Vyvanse; LDX) on executive function and prefrontal cortex activation in menopausal women ages 45-57, who report subjective cognitive difficulties. This protocol will recruit women from Dr. Epperson's ongoing study, Protocol ...
What is the current status of trial NCT01977625?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 18 participants. The study started on 2011-12. Estimated completion is 2014-04.
What interventions are being tested in trial NCT01977625?
The interventions under investigation include: Placebo (OTHER), Lisdexamfetamine (DRUG).
Who is sponsoring clinical trial NCT01977625?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.